SMTL ID : 7uvf.1

Crystal structure of ZED8 Fab complex with CD8 alpha

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.60 Å

Oligo State

hetero-2-2-2-mer

Ligands

1 x GOL: GLYCEROL(Non-functional Binders)

GOL.1: 5 residues within 4Å: Chain B: L.14, G.15, E.16 Chain E: F.94 Chain F: L.59 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:L.14 Water bridges: B:N.13

2 x CL: CHLORIDE ION(Non-functional Binders)

CL.2: 8 residues within 4Å: Chain C: Y.33, H.35, R.50, G.99, Y.100, G.101, Y.102, Y.103 Ligand excluded by PLIP CL.3: 8 residues within 4Å: Chain F: Y.33, H.35, R.50, G.99, Y.100, G.101, Y.102, Y.103 Ligand excluded by PLIP

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ogasawara, A. et al., Preclinical development of ZED8, an 89 Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. Eur J Nucl Med Mol Imaging (2023)

Release Date

2022-10-12

Peptides

T-cell surface glycoprotein CD8 alpha chain: AB
Immunoglobulin heavy chain: CF
Immunoglobulin light chain: DE

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
H

F
X

D
L

E
Y

T-cell surface glycoprotein CD8 alpha chain

Immunoglobulin heavy chain

Immunoglobulin light chain